Neuroprotective effects of early antiretrovirals in vertical HIV infection.
We performed a retrospective study of a series of 58 of 189 vertically HIV-1 infected children who went on to develop progressive HIV-1-associated encephalopathy to assess real-life effects of early antiretroviral therapy on neurologic outcome. Our findings clearly indicate that antiretroviral therapy before the onset of neurologic symptoms delayed presentation of progressive HIV-1-associated encephalopathy, with an additional beneficial effect on survival.
Sánchez-Ramón
Silvia
S
Unit of Neuroimmunology, Laboratory of Immuno-Molecular Biology, Madrid, Spain
Resino
Salvador
S
Bellón Cano
José M
JM
Ramos
José T
JT
Gurbindo
Dolores
D
Muñoz-Fernández
Angeles
A
D015526:AIDS Dementia Complex / Q000188:drug therapy / Q000517:prevention & control*; D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D013997:Time Factors
D044966:Anti-Retroviral Agents; D018696:Neuroprotective Agents